Foghorn Therapeutics (FHTX) Operating Leases (2020 - 2025)
Historic Operating Leases for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $22.5 million.
- Foghorn Therapeutics' Operating Leases fell 2564.69% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 2564.69%. This contributed to the annual value of $28.1 million for FY2024, which is 3773.66% down from last year.
- Per Foghorn Therapeutics' latest filing, its Operating Leases stood at $22.5 million for Q3 2025, which was down 2564.69% from $23.7 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Operating Leases registered a high of $62.3 million during Q1 2021, and its lowest value of $22.5 million during Q3 2025.
- Its 5-year average for Operating Leases is $42.1 million, with a median of $43.5 million in 2023.
- Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 697.91% in 2021, then plummeted by 3773.66% in 2024.
- Over the past 5 years, Foghorn Therapeutics' Operating Leases (Quarter) stood at $58.3 million in 2021, then fell by 11.7% to $51.5 million in 2022, then decreased by 12.49% to $45.1 million in 2023, then plummeted by 37.74% to $28.1 million in 2024, then dropped by 19.72% to $22.5 million in 2025.
- Its Operating Leases stands at $22.5 million for Q3 2025, versus $23.7 million for Q2 2025 and $25.7 million for Q1 2025.